Skip to product information
Tepotinib – LuciTepo
KSh416,000.00
|
What it treats: |
|
|
metastatic non-small cell lung cancer (NSCLC) |
Tepotinib is approved for adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations, a genetic mutation occurring in approximately 3–4% of NSCLC cases. This includes both treatment-naïve and previously treated patients. It targets MET signaling, which drives tumor growth in NSCLC with METex14 skipping mutations, leading to improved tumor response and prolonged progression-free survival. It is particularly valuable for patients with this specific mutation, as METex14 alterations are associated with poor prognosis and limited response to standard therapies like chemotherapy or immunotherapy alone. |